TY - JOUR
T1 - Resilience in schizophrenia
T2 - A comparative study between a remote island and an urban area in Japan
AU - Yoshida, Kazunari
AU - Suzuki, Takefumi
AU - Imasaka, Yasushi
AU - Kubo, Ken ichiro
AU - Mizuno, Yuya
AU - Saruta, Juri
AU - Tsukinoki, Keiichi
AU - Mimura, Masaru
AU - Uchida, Hiroyuki
N1 - Funding Information:
Dr. Yoshida has received manuscript fees or speaker's honoraria from Meiji Seika Pharma, Sumitomo Dainippon Pharma, and Eli Lilly within the past three years. Dr. Suzuki has received manuscript or speaker's fees from Astellas, Sumitomo Dainippon Pharma, Eli Lilly, Elsevier Japan, Janssen Pharmaceuticals, Meiji Seika Pharma, Novartis, Otsuka Pharmaceutical, and Wiley Japan within the past three years. Dr. Imasaka has received speaker's fees from Sumitomo Dainippon Pharma, Eli Lilly, Janssen Pharmaceuticals, Meiji Seika Pharma, and Otsuka Pharmaceutical within the past three years. Dr. Kubo has no conflicts of interest to declare within the past three years. Dr. Mizuno has received manuscript fees or speaker's honoraria from Astellas, Sumitomo Dainippon Pharma, and Eli Lilly, textbook royalties from Chugai-Igakusha, Seiwa Publishers, and Sentan-Igakusha within the past three years. Dr. Saruta has received Grant-in-Aid for Young Scientists (B) (KAKENHI Grant Number 26861582) within the past three years. Dr. Tsukinoki has received Grant-in-Aid for Challenging Exploratory Research (KAKENHI Grant Number 26670821) within the past three years. Dr. Mimura has received grants and/or speaker's honoraria from Asahi Kasei Pharma, Astellas, Daiichi Sankyo, Sumitomo Dainippon Pharma, Eisai, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, Meiji Seika Pharma, Mochida Pharmaceutical, MSD, Novartis, Otsuka Pharmaceutical, Pfizer, Tsumura, Shionogi, Takeda, Tanabe Mitsubishi Pharma, and Yoshitomi Yakuhin within the past three years. Dr. Uchida has received grants from Astellas, Eisai, Otsuka Pharmaceutical, GlaxoSmithKline, Shionogi, Sumitomo Dainippon Pharma, Eli Lilly, Mochida Pharmaceutical, Meiji Seika Pharma, and Yoshitomi Yakuhin and speaker's honoraria from Otsuka Pharmaceutical, Eli Lilly, Shionogi, GlaxoSmithKline, Yoshitomi Yakuhin, Sumitomo Dainippon Pharma, Meiji Seika Pharma, Abbvie, MSD, and Janssen Pharmaceuticals within the past three years.
Funding Information:
No funding was provided for the present analysis. We gratefully acknowledge the assistance of the staff in Ohshima Medical Center, Ohizumi Hospital, Ohizumi Mental Clinic and Inokashira Hospital. The authors thank Drs. Ryoko Yamazawa, Jo Okubo, Kaoru Shimizu, Hitoshi Sakurai and Minako Sato for their valuable advice; Ms. Ai Otani and Ms. Aki Endo for their administrative support.
Publisher Copyright:
© 2016 Elsevier B.V.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - The resilience levels between patients with schizophrenia residing in a rural island and a metropolitan area in Tokyo, Japan, was compared and the factors associated with resilience were explored. The Resilience Scale (RS) and EuroQol were assessed, together with biological markers and multiple demographic variables. No significant difference was found in the RS scores between the two groups (40 subjects each). However, longer duration of illness and higher EuroQol score were significantly associated with a greater RS score, which indicates that potentially successful adaptation and subjective perspectives appear more pertinent than the degree of urbanicity in determining resilience levels.
AB - The resilience levels between patients with schizophrenia residing in a rural island and a metropolitan area in Tokyo, Japan, was compared and the factors associated with resilience were explored. The Resilience Scale (RS) and EuroQol were assessed, together with biological markers and multiple demographic variables. No significant difference was found in the RS scores between the two groups (40 subjects each). However, longer duration of illness and higher EuroQol score were significantly associated with a greater RS score, which indicates that potentially successful adaptation and subjective perspectives appear more pertinent than the degree of urbanicity in determining resilience levels.
KW - Duration of illness
KW - Quality of life
KW - Resilience
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=84958125059&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958125059&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2016.01.030
DO - 10.1016/j.schres.2016.01.030
M3 - Article
C2 - 26805409
AN - SCOPUS:84958125059
SN - 0920-9964
VL - 171
SP - 92
EP - 96
JO - Schizophrenia Research
JF - Schizophrenia Research
IS - 1-3
ER -
